RedHill Biopharma shares are trading lower. The company announced the FDA has granted rare pediatric disease designation to opaganib for treatment of neuroblastoma.

Benzinga Newsdesk www.benzinga.com Positive 66.5%

Neg 0% Neu 0% Pos 66.5%

Comments

No comments yet. Be the first!